XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.20.2

Net Loss Per Share (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Earnings Per Share [Abstract] |
Schedule of Diluted Net Income (Loss) Per Share | The following tables reconcile the components of the numerator and denominator included in the calculation of diluted net income (loss) per share:
|  | Three Months Ended September 30,
|  | 2020 |  | 2019
Numerator |  |  |  |
Net income (loss) attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net income (loss) per share) |  | $ | 19,171,336 |  |  | $ | (23,090,693) |
Adjustment for decrease in fair value of derivative liability and interest expense |  | — |  |  | (2,177,250) |
Numerator for use in diluted income (loss) per share |  | $ | 19,171,336 |  |  | $ | (25,267,943) |
Denominator |  |  |  |
Weighted average number of common shares outstanding (denominator for use in basic net income (loss) per share) |  | 165,355,540 |  |  | 99,007,985 |
Effect of dilutive potential common shares |  | 9,020,862 |  |  | 3,799,071 |
Denominator for use in diluted net income (loss) per share |  | 174,376,402 |  |  | 102,807,056 |
Net income (loss) per share, diluted |  | $ | 0.11 |  |  | $ | (0.25) |
Net income (loss) per share, basic |  | $ | 0.12 |  |  | $ | (0.23) |
|  | Nine Months Ended September 30,
|  | 2020 |  | 2019
Numerator |  |  |  |
Net loss attributed to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share) |  | $ | (142,072,777) |  |  | $ | (81,697,181) |
Adjustment for decrease in fair value of derivative liability and interest expense |  | — |  |  | — |
Numerator for use in diluted loss per share |  | $ | (142,072,777) |  |  | $ | (81,697,181) |
Denominator |  |  |  |
Weighted average number of common shares outstanding (denominator for use in basic net loss per share) |  | 148,656,454 |  |  | 98,204,375 |
Effect of dilutive potential common shares |  | — |  |  | — |
Denominator for use in diluted net loss per share |  | 148,656,454 |  |  | 98,204,375 |
Net loss per share, diluted |  | $ | (0.96) |  |  | $ | (0.83) |
Net loss per share, basic |  | $ | (0.96) |  |  | $ | (0.83) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table summarizes potential shares of common stock that were excluded from the diluted net income (loss) per share calculation because of their anti-dilutive effect for the three months ended September 30, 2020 and 2019:
Common Stock Equivalents | 2020 |  | 2019 |  |
Options to purchase common stock | 119,438 |  |  | 9,971,297 |  |  |
Service-based restricted stock units | — |  |  | 2,121,359 |  |  |
Convertible preferred stock | 3,309 |  |  | 8,456 |  |  |
Convertible notes | 11,039,574 |  |  | 14,585,653 |  |  |
August 2019 Bonds | — |  |  | — |  |  |
December 2019 Bonds | 1,009,450 |  |  | — |  |  |
Total | 12,171,771 |  |  | 26,686,765 |  |  |
The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the nine months ended September 30, 2020 and 2019:
Common Stock Equivalents | 2020 |  | 2019 |  |
Options to purchase common stock | 9,290,347 |  |  | 9,971,297 |  |  |
Service-based restricted stock units | 2,586,915 |  |  | 2,121,359 |  |  |
Performance-based restricted stock units | 663,353 |  |  | — |  |  |
Convertible preferred stock | 3,309 |  |  | 8,456 |  |  |
Convertible notes | 11,039,574 |  |  | 14,585,653 |  |  |
August 2019 Bonds | — |  |  | 3,799,071 |  |  |
December 2019 Bonds | 1,009,450 |  |  | — |  |  |
Total | 24,592,948 |  |  | 30,485,836 |  |  |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration